Showing 7961-7970 of 9427 results for "".
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED
- Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minorshttps://practicaldermatology.com/news/allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors/2458125/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Dr. Jacqualyn Fouse Named Executive Chairman of Dermavanthttps://practicaldermatology.com/news/dr-jacqualyn-fouse-named-executive-chairman-of-dermavent/2458127/Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory approval, commercializing three investigational d
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple
- And Then There Were Three: Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://practicaldermatology.com/news/and-then-there-were-three-alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2458158/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- Retailers Charge Women More Than Men for Minoxidilhttps://practicaldermatology.com/news/retailers-charge-women-more-than-men-for-minoxidil/2458163/Women pay an average of 40 percent more than men for minoxidil foams, according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania in JAMA Dermatology</